Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

719900

Sigma-Aldrich

Resomer® RG 504 H, Poly(D,L-lactide-co-glycolide)

acid terminated, lactide:glycolide 50:50, Mw 38,000-54,000

Synonym(s):

PLGA

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
[C3H4O2]x[C2H2O2]y
CAS Number:
26780-50-7
MDL number:
MFCD00131930
UNSPSC Code:
12162002
NACRES:
NA.23
Pricing and availability is not currently available.

form

amorphous

feed ratio

lactide:glycolide 50:50

mol wt

Mw 38,000-54,000

degradation timeframe

<3 months

viscosity

0.45-0.60 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)

transition temp

Tg 46-50 °C

storage temp.

2-8°C

SMILES string

O2C(C(=O)OC(C2=O)C)C.O1CC(=O)OCC1=O

InChI

1S/C6H8O4.C4H4O4/c1-3-5(7)10-4(2)6(8)9-3;5-3-1-7-4(6)2-8-3/h3-4H,1-2H3;1-2H2

InChI key

LCSKNASZPVZHEG-UHFFFAOYSA-N

Application

Resomer® RG 504 H, Poly(D, L-Lactide-co-Glycolide) can be used to fabricate a biodegradable hemostyptic device for safe and locally controlled release of thrombin which promotes local blood clot formation.

It can be used to preparepolymer nanospheres for encapsulating CuO, to form stimuli-responsivemultifunctional nanocarriers.

Legal Information

Product of Evonik
RESOMER is a registered trademark of Evonik Rohm GmbH

related product

Product No.
Description
Pricing

911593

NanoFabTx™ microfluidic - nano, device kit for synthesis of 100-200 nm nanoparticles and liposomes

911860

NanoFabTx™ microfluidic - micro, device kit for synthesis of 1-5 μm particles

911879

NanoFabTx™ microfluidic - micro, device kit for synthesis of 10-30 μm particles

909637

NanoFabTx™ PLGA-nano, for synthesis of 100 and 200 nm particles

912212

NanoFabTx™ PLGA-micro, for synthesis of 10-30 um particles

912220

NanoFabTx™ PLGA-micro, for synthesis of 1-5 μm particles

920436

NanoFabTx™ PEG-PLA drug formulation screening kit, for synthesis of PEGylated nanoparticles

915408

NanoFabTx™ PEGylated nanoparticle formulation screening kit

917796

NanoFabTx™ PEG-PLGA drug formulation screening kit, for synthesis of PEGylated nanoparticles

918881

NanoFabTx™ PEG-PCL drug formulation screening kit, for synthesis of PEGylated nanoparticles

918075

NanoFabTx™ PLA-nano, for synthesis of 100 and 200 nm particles

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCX6489
MKCV5944
BCCH5449
BCCG3293
BCCD7787

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hossein Kamali et al.
Materials science & engineering. C, Materials for biological applications, 96, 561-575 (2019-01-05)
An in situ forming gel (ISFG) of buprenorphine (BP) was prepared using PLGA-PEG-PLGA (triblock) and N‑methyl‑2‑pyrrolidone as solvent for decreasing the initial burst release. Supercritical CO2 method was used for ring opening polymerization of triblock. The optimum formulation of ISFG
Niranjan G Kotla et al.
Nanomaterials (Basel, Switzerland), 9(9) (2019-09-05)
There is a pressing clinical need for advanced colon-specific local drug delivery systems that can provide major advantages in treating diseases associated with the colon, such as inflammatory bowel disease (IBD) and colon cancer. A precise colon targeted drug delivery
Kyle E Broaders et al.
Proceedings of the National Academy of Sciences of the United States of America, 106(14), 5497-5502 (2009-03-27)
Materials that combine facile synthesis, simple tuning of degradation rate, processability, and biocompatibility are in high demand for use in biomedical applications. We report on acetalated dextran, a biocompatible material that can be formed into microparticles with degradation rates that
Igor Jeroukhimov et al.
Journal of the American College of Surgeons, 218(1), 102-107 (2013-11-12)
Chronic pain after inguinal hernia repair occurs in 16% to 62% of patients. The underlying mechanism probably involves sensory nerve damage and abnormal healing that might be influenced by the materials chosen for the procedure. We hypothesize that nonabsorbable sutures
Maria Kirzhner et al.
Ophthalmology, 120(6), 1300-1304 (2013-02-13)
To compare wrapped and polymer-coated hydroxyapatite implants in children undergoing primary enucleation with no adjuvant therapies. Retrospective, interventional cohort study. All children undergoing primary enucleation without adjuvant therapies between 1999 and 2009 at a tertiary pediatric cancer hospital. Review and
View All Related Papers

Articles

RESOMER® - Biodegradable Polymers for Sutures, Medical Devices, Drug Delivery Systems and Tissue Engineering

Interest in utilizing biodegradable polymers for biomedical applications has grown since the 1960s.

Poly(Glycerol Sebacate) in Tissue Engineering

Synthetic aliphatic polyesters dominate resorbable biomaterials in clinical use.

Biodegradable Polyester Nanoparticle Formation

AliAliphatic polyesters, including polylactide and polyglycolide, are biodegradable polymers widely used in medical applications.

Therapeutic Nanoparticles Harness Myeloid Cells for Brain Tumor-Targeted Delivery and Immunomodulation

Immunosuppressive tumor-associated myeloid cells (TAMC) are responsible for glioblastoma (GBM) resistance to immunotherapies and existing standard of care treatments. This mini-review highlights recent progress in implementing nanotechnology in advancing TAMC-targeted therapies for GBM.

See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service